Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Theraclone and Japanese pharma Zenyaku Kogyo announce influenza antibody alliance
November 2009
SHARING OPTIONS:

TOKYO—Theraclone Sciences Inc., a Seattle-based biotechnology company, and Japanese pharma Zenyaku Kogyo Co. Ltd., announced in October that they have entered into a multiyear research and development agreement to use Theraclone's I-STAR technology to discover broadly protective monoclonal antibodies for the treatment of pandemic influenza and severe seasonal influenza. Zenyaku Kogyo will receive an option to exclusive antibody rights in Asia as well as an option in the territory to potential vaccine candidates stemming from the discovery research. In exchange for these rights, Theraclone will receive an undisclosed, upfront cash payment. If Zenyaku Kogyo exercises its option, Theraclone is entitled to receive success-based R&D milestones totaling more than $18 million through Phase 1 clinical studies, clinical milestone payments and royalties from potential future sales in the territory and development and commercial rights in non-Asian countries.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.